Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Bought by Barclays PLC

Barclays PLC grew its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 280.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,561 shares of the biotechnology company’s stock after acquiring an additional 48,313 shares during the quarter. Barclays PLC owned about 0.11% of Aldeyra Therapeutics worth $353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALDX. US Bancorp DE acquired a new stake in Aldeyra Therapeutics during the third quarter worth about $30,000. Paloma Partners Management Co acquired a new stake in Aldeyra Therapeutics during the third quarter worth about $62,000. The Manufacturers Life Insurance Company increased its stake in Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 2,729 shares during the last quarter. King Wealth Management Group increased its stake in Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 2,700 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Aldeyra Therapeutics by 253.3% during the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 10,201 shares during the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $5.45 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics, Inc has a 12 month low of $2.71 and a 12 month high of $6.55. The business has a 50-day moving average of $5.02 and a two-hundred day moving average of $4.85.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.